Melioidosis: Evolving Concepts in Epidemiology, Pathogenesis, and Treatment
暂无分享,去创建一个
[1] L. Waller,et al. Contact investigation of melioidosis cases reveals regional endemicity in Puerto Rico. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] P. Newton,et al. Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei , 2014, International journal of antimicrobial agents.
[3] B. Currie,et al. Autochthonous Melioidosis in Humans, Madagascar, 2012 and 2013 , 2014, Emerging infectious diseases.
[4] K. Fuursted,et al. Mycotic aneurysm caused by Burkholderia pseudomallei in a previously healthy returning traveller , 2014, BMJ Case Reports.
[5] H. D. Liggitt,et al. NLRC4 and TLR5 Each Contribute to Host Defense in Respiratory Melioidosis , 2014, PLoS neglected tropical diseases.
[6] B. Currie,et al. Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. , 2014, International journal of antimicrobial agents.
[7] A. Hoffmaster,et al. Fatal Burkholderia pseudomallei infection initially reported as a Bacillus species, Ohio, 2013. , 2014, The American journal of tropical medicine and hygiene.
[8] Pei-Shih Chen,et al. The Concentrations of Ambient Burkholderia Pseudomallei during Typhoon Season in Endemic Area of Melioidosis in Taiwan , 2014, PLoS Neglected Tropical Diseases.
[9] A. Mackay-Sim,et al. Burkholderia pseudomallei Penetrates the Brain via Destruction of the Olfactory and Trigeminal Nerves: Implications for the Pathogenesis of Neurological Melioidosis , 2014, mBio.
[10] A. Hoffmaster,et al. Burkholderia pseudomallei Type G in Western Hemisphere , 2014, Emerging infectious diseases.
[11] D. Dance,et al. International Journal of Antimicrobial Agents Review Treatment and Prophylaxis of Melioidosis , 2022 .
[12] Erin P. Price,et al. Variable Virulence Factors in Burkholderia pseudomallei (Melioidosis) Associated with Human Disease , 2014, PloS one.
[13] N. Day,et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial , 2014, The Lancet.
[14] Direk Limmathurotsakul,et al. Development of a Prototype Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis , 2014, PLoS neglected tropical diseases.
[15] T. West,et al. Common TLR1 Genetic Variation Is Not Associated with Death from Melioidosis, a Common Cause of Sepsis in Rural Thailand , 2014, PloS one.
[16] H. D. Liggitt,et al. The Role of NOD2 in Murine and Human Melioidosis , 2014, The Journal of Immunology.
[17] T. West,et al. Screen of whole blood responses to flagellin identifies TLR5 variation associated with outcome in melioidosis , 2013, Genes and Immunity.
[18] B. Currie,et al. Recurrent Melioidosis in the Darwin Prospective Melioidosis Study: Improving Therapies Mean that Relapse Cases Are Now Rare , 2013, Journal of Clinical Microbiology.
[19] N. Day,et al. Rapid Detection of Burkholderia pseudomallei in Blood Cultures Using a Monoclonal Antibody-Based Immunofluorescent Assay , 2013, The American journal of tropical medicine and hygiene.
[20] T. William,et al. Reliability of Automated Biochemical Identification of Burkholderia pseudomallei Is Regionally Dependent , 2013, Journal of Clinical Microbiology.
[21] A. Cheng,et al. Osteomyelitis and septic arthritis from infection with Burkholderia pseudomallei: A 20-year prospective melioidosis study from northern Australia. , 2013, Journal of orthopaedics.
[22] R. Heyderman,et al. Human Melioidosis, Malawi, 2011 , 2013, Emerging infectious diseases.
[23] T. West,et al. Impaired TLR5 Functionality Is Associated with Survival in Melioidosis , 2013, The Journal of Immunology.
[24] B. Currie,et al. Surprisingly Low Seroprevalence of Burkholderia pseudomallei in Exposed Healthy Adults in the Darwin Region of Tropical Australia Where Melioidosis Is Highly Endemic , 2013, Clinical and Vaccine Immunology.
[25] Xiangyang Liu,et al. Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. , 2013, Journal of natural products.
[26] A. Simpson,et al. Clinical Definitions of Melioidosis , 2013, The American journal of tropical medicine and hygiene.
[27] B. Currie,et al. Melioidosis and the kidney , 2013, Nephrology.
[28] Robin Patel,et al. Importance of Using Bruker's Security-Relevant Library for Biotyper Identification of Burkholderia pseudomallei, Brucella Species, and Francisella tularensis , 2013, Journal of Clinical Microbiology.
[29] J. Vadivelu,et al. Burkholderia vaccines: are we moving forward? , 2013, Front. Cell. Inf. Microbio..
[30] N. Day,et al. Activities of Daily Living Associated with Acquisition of Melioidosis in Northeast Thailand: A Matched Case-Control Study , 2013, PLoS neglected tropical diseases.
[31] N. Ketheesan,et al. ELISA and immuno-polymerase chain reaction assays for the sensitive detection of melioidosis. , 2013, Diagnostic microbiology and infectious disease.
[32] H. D. Liggitt,et al. Murine pulmonary infection and inflammation induced by inhalation of Burkholderia pseudomallei , 2012, International journal of experimental pathology.
[33] Theresa L. Smith,et al. Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010 , 2012, Emerging infectious diseases.
[34] G. Maneenil,et al. Neonatal Melioidosis: Systematic Review of the Literature , 2012, The Pediatric infectious disease journal.
[35] D. Butler. Viral research faces clampdown , 2012, Nature.
[36] H. Schweizer. When it comes to drug discovery not all Gram‐negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different , 2012, Microbial biotechnology.
[37] P. Keim,et al. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. , 2012, Environmental microbiology.
[38] Talima Pearson,et al. Comparison of TaqMan PCR Assays for Detection of the Melioidosis Agent Burkholderia pseudomallei in Clinical Specimens , 2012, Journal of Clinical Microbiology.
[39] U. Parameswaran,et al. Melioidosis at Royal Darwin Hospital in the big 2009–2010 wet season: comparison with the preceding 20 years , 2012, The Medical journal of Australia.
[40] D. Engelthaler,et al. Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia , 2012, PloS one.
[41] A. Cheng,et al. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] H. Schweizer,et al. Proteomic analysis of colony morphology variants of Burkholderia pseudomallei defines a role for the arginine deiminase system in bacterial survival , 2012, Journal of proteomics.
[43] N. Day,et al. Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes , 2012, PLoS neglected tropical diseases.
[44] A. Simpson,et al. Development of an acute model of inhalational melioidosis in the common marmoset (Callithrix jacchus) , 2011, International journal of experimental pathology.
[45] D. Rice,et al. A Burkholderia pseudomallei Toxin Inhibits Helicase Activity of Translation Factor eIF4A , 2011, Science.
[46] H. Schweizer,et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei , 2011, Proceedings of the National Academy of Sciences.
[47] L. Price,et al. Molecular Investigations of a Locally Acquired Case of Melioidosis in Southern AZ, USA , 2011, PLoS neglected tropical diseases.
[48] N. Day,et al. Survey of Antimicrobial Resistance in Clinical Burkholderia pseudomallei Isolates over Two Decades in Northeast Thailand , 2011, Antimicrobial Agents and Chemotherapy.
[49] T. West,et al. Toll-Like Receptor 4 Region Genetic Variants are Associated with Susceptibility to Melioidosis , 2011, Genes and Immunity.
[50] Theresa L. Smith,et al. Epidemiology and Investigation of Melioidosis, Southern Arizona , 2011, Emerging infectious diseases.
[51] H. Atkins,et al. Antimicrobials for bacterial bioterrorism agents. , 2011, Future microbiology.
[52] P. Harris,et al. Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. , 2011, International journal of antimicrobial agents.
[53] P. Dawyndt,et al. Classification and identification of the Burkholderia cepacia complex: Past, present and future. , 2011, Systematic and applied microbiology.
[54] D. DeShazer,et al. The Cluster 1 Type VI Secretion System Is a Major Virulence Determinant in Burkholderia pseudomallei , 2011, Infection and Immunity.
[55] A. Cheng,et al. The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study , 2010, PLoS neglected tropical diseases.
[56] N. Day,et al. Increasing Incidence of Human Melioidosis in Northeast Thailand , 2010, The American journal of tropical medicine and hygiene.
[57] H. Schweizer,et al. Present and future therapeutic strategies for melioidosis and glanders , 2010, Expert review of anti-infective therapy.
[58] K. Goh,et al. Melioidosis in a Tropical City State, Singapore , 2009, Emerging infectious diseases.
[59] A. Cheng,et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. , 2009, The Journal of urology.
[60] A. Cheng,et al. Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis , 2009, Antimicrobial Agents and Chemotherapy.
[61] A. Mackay-Sim,et al. Nasal-associated lymphoid tissue and olfactory epithelium as portals of entry for Burkholderia pseudomallei in murine melioidosis. , 2009, The Journal of infectious diseases.
[62] A. Cheng,et al. The global distribution of Burkholderia pseudomallei and melioidosis: an update. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[63] A. Haque,et al. Burkholderia pseudomallei: animal models of infection. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[64] A. Cheng,et al. Intensity of exposure and incidence of melioidosis in Thai children. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[65] Raymond K. Auerbach,et al. Genomic islands from five strains of Burkholderia pseudomallei , 2008, BMC Genomics.
[66] N. Day,et al. A Simple Scoring System to Differentiate between Relapse and Re-Infection in Patients with Recurrent Melioidosis , 2008, PLoS neglected tropical diseases.
[67] K. Gibney,et al. Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[68] T. West,et al. Strategies to Reduce Mortality from Bacterial Sepsis in Adults in Developing Countries , 2008, PLoS medicine.
[69] Theresa L. Smith,et al. Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. mallei , 2008, Emerging infectious diseases.
[70] T. Coenye,et al. Diversity and occurrence of Burkholderia spp. in the natural environment. , 2008, FEMS microbiology reviews.
[71] Ryan T Novak,et al. Recovery of a Burkholderia thailandensis-like isolate from an Australian water source , 2008, BMC Microbiology.
[72] A. Cheng,et al. Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. , 2008, The American journal of tropical medicine and hygiene.
[73] N. Day,et al. Loop-Mediated Isothermal Amplification Method Targeting the TTS1 Gene Cluster for Detection of Burkholderia pseudomallei and Diagnosis of Melioidosis , 2007, Journal of Clinical Microbiology.
[74] Raymond K. Auerbach,et al. A Horizontal Gene Transfer Event Defines Two Distinct Groups within Burkholderia pseudomallei That Have Dissimilar Geographic Distributions , 2007, Journal of bacteriology.
[75] P. Newton,et al. Accuracy of Burkholderia pseudomallei Identification Using the API 20NE System and a Latex Agglutination Test , 2007, Journal of Clinical Microbiology.
[76] N. Day,et al. Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] A. Cheng,et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[78] T. van der Poll,et al. Toll-Like Receptor 2 Impairs Host Defense in Gram-Negative Sepsis Caused by Burkholderia pseudomallei (Melioidosis) , 2007, PLoS medicine.
[79] W. Ko,et al. Melioidosis Outbreak after Typhoon, Southern Taiwan , 2007, Emerging infectious diseases.
[80] N. Day,et al. Biological Relevance of Colony Morphology and Phenotypic Switching by Burkholderia pseudomallei , 2006, Journal of bacteriology.
[81] T. Inglis,et al. Melioidosis in the Americas. , 2006, The American journal of tropical medicine and hygiene.
[82] Ryan T Novak,et al. Clinical Evaluation of a Type III Secretion System Real-Time PCR Assay for Diagnosing Melioidosis , 2006, Journal of Clinical Microbiology.
[83] N. Day,et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. , 2006, The American journal of tropical medicine and hygiene.
[84] Nicholas J. White,et al. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei , 2006, Nature Reviews Microbiology.
[85] A. Cheng,et al. Indirect hemagglutination assay in patients with melioidosis in northern Australia. , 2006, The American journal of tropical medicine and hygiene.
[86] Ryan T Novak,et al. Development and Evaluation of a Real-Time PCR Assay Targeting the Type III Secretion System of Burkholderia pseudomallei , 2006, Journal of Clinical Microbiology.
[87] A. Cheng,et al. Short report: disease severity and outcome of melioidosis in HIV coinfected individuals. , 2005, The American journal of tropical medicine and hygiene.
[88] P. Newton,et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] A. Cheng,et al. Comparison of Ashdown's Medium, Burkholderia cepacia Medium, and Burkholderia pseudomallei Selective Agar for Clinical Isolation of Burkholderia pseudomallei , 2005, Journal of Clinical Microbiology.
[90] N. Day,et al. Melioidosis in 6 tsunami survivors in southern Thailand. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[91] I. Bastian,et al. Melioidosis in Tsunami Survivors , 2005, Emerging infectious diseases.
[92] A. Cheng,et al. Rapid Immunofluorescence Microscopy for Diagnosis of Melioidosis , 2005, Clinical Diagnostic Laboratory Immunology.
[93] A. Allworth. Tsunami lung: a necrotising pneumonia in survivors of the Asian tsunami , 2005, The Medical journal of Australia.
[94] A. Cheng,et al. Melioidosis: Epidemiology, Pathophysiology, and Management , 2005, Clinical Microbiology Reviews.
[95] G. Crawford,et al. Cutaneous Melioidosis in a Man Who Was Taken as a Prisoner of War by the Japanese during World War II , 2005, Journal of Clinical Microbiology.
[96] R. Devinney,et al. The Capsular Polysaccharide of Burkholderia pseudomallei Contributes to Survival in Serum by Reducing Complement Factor C3b Deposition , 2005, Infection and Immunity.
[97] A. Ralph,et al. Transmission of Burkholderia pseudomallei via breast milk in northern Australia. , 2004, The Pediatric infectious disease journal.
[98] R. Ulrich,et al. Role of quorum sensing in the pathogenicity of Burkholderia pseudomallei. , 2004, Journal of medical microbiology.
[99] P. Vandamme,et al. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe , 2004, Thorax.
[100] R. Speare,et al. Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. , 2004, Clinical immunology.
[101] Kim Rutherford,et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[102] O. White,et al. Structural flexibility in the Burkholderia mallei genome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[103] B. Currie,et al. The neuropathology of melioidosis: two cases and a review of the literature. , 2004, Clinical neuropathology.
[104] B. Currie,et al. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters , 2004, Tropical medicine & international health : TM & IH.
[105] N. Anstey,et al. Outcomes of Patients with Melioidosis Treated with Meropenem , 2004, Antimicrobial Agents and Chemotherapy.
[106] B. Currie,et al. Intensity of Rainfall and Severity of Melioidosis, Australia , 2003, Emerging infectious diseases.
[107] B. Currie. Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions , 2003, European Respiratory Journal.
[108] B. Spratt,et al. Multilocus Sequence Typing and Evolutionary Relationships among the Causative Agents of Melioidosis and Glanders, Burkholderia pseudomallei and Burkholderia mallei , 2003, Journal of Clinical Microbiology.
[109] J. Jeddeloh,et al. Biodefense-Driven Murine Model of Pneumonic Melioidosis , 2003, Infection and Immunity.
[110] R. Norton,et al. Comparison of Automated and Nonautomated Systems for Identification of Burkholderia pseudomallei , 2002, Journal of Clinical Microbiology.
[111] M. Stevens,et al. An Inv/Mxi‐Spa‐like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen , 2002, Molecular microbiology.
[112] N. Ketheesan,et al. Demonstration of a cell-mediated immune response in melioidosis. , 2002, The Journal of infectious diseases.
[113] Y. Sitoh,et al. Cerebral melioidosis in Singapore: a review of five cases. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[114] S. Deitchman,et al. Glanders in a military research microbiologist. , 2001, The New England journal of medicine.
[115] N. Anstey,et al. A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. , 2001, The American journal of tropical medicine and hygiene.
[116] J. Bartlett,et al. Glanders in a military research microbiologist. , 2001, New England Journal of Medicine.
[117] N. Ketheesan,et al. Burkholderia pseudomallei virulence: definition, stability and association with clonality. , 2001, Microbes and infection.
[118] D. Fisher,et al. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. , 2001, International journal of antimicrobial agents.
[119] N. Anstey,et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[120] N. Anstey,et al. Melioidosis: acute and chronic disease, relapse and re-activation. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[121] N. Anstey,et al. The epidemiology of melioidosis in Australia and Papua New Guinea. , 2000, Acta tropica.
[122] A. Leelarasamee. Melioidosis in Southeast Asia. , 2000, Acta tropica.
[123] B. Currie,et al. Animal melioidosis in Australia. , 2000, Acta tropica.
[124] W. Chaowagul,et al. Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe meliodosis. , 1999, Human immunology.
[125] A. Simpson,et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[126] Y. Suputtamongkol,et al. Risk factors for melioidosis and bacteremic melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[127] A. Simpson,et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[128] D. DeShazer,et al. The type II O‐antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence , 1998, Molecular microbiology.
[129] M. Wheelis. First shots fired in biological warfare , 1998, Nature.
[130] N. White,et al. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. , 1996, The Journal of antimicrobial chemotherapy.
[131] A. Hall,et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. , 1994, International journal of epidemiology.
[132] N. White,et al. Relapse in melioidosis: incidence and risk factors. , 1993, The Journal of infectious diseases.
[133] N. Anstey,et al. Neurological melioidosis: seven cases from the Northern Territory of Australia. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[134] N. White,et al. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. , 1991, The Journal of antimicrobial chemotherapy.
[135] D. Dance. Melioidosis: the tip of the iceberg? , 1991, Clinical Microbiology Reviews.
[136] N. White,et al. The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. , 1990, Journal of medical microbiology.
[137] N. White,et al. HALVING OF MORTALITY OF SEVERE MELIOIDOSIS BY CEFTAZIDIME , 1989, The Lancet.
[138] N. White,et al. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. , 1989, The Journal of antimicrobial chemotherapy.
[139] N. White,et al. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. , 1989, Journal of clinical pathology.
[140] A. Leelarasamee,et al. Melioidosis: review and update. , 1989, Reviews of infectious diseases.
[141] N. White,et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. , 1989, The Journal of infectious diseases.
[142] N. White,et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. , 1989, The Journal of infectious diseases.
[143] N. White,et al. ANTIBIOTIC RESISTANCE IN PSEUDOMONAS PSEUDOMALLEI , 1988, The Lancet.
[144] K. Silpapojakul,et al. Acute Pseudomonas pseudomallei pneumonia and septicemia following aspiration of contaminated water: a case report. , 1985, Southeast Asian Journal of Tropical Medicine and Public Health.
[145] W. Tsai,et al. Pseudomonas pseudomallei infection from drowning: the first reported case in Taiwan , 1985, Journal of clinical microbiology.
[146] R. Guard,et al. The prevalence of human melioidosis in Northern Queensland. , 1984, The American journal of tropical medicine and hygiene.
[147] C. Howe,et al. The pseudomallei group: a review. , 1971, The Journal of infectious diseases.
[148] King Cw. Chronic or latent melioidosis. , 1971 .
[149] C. Kingston. CHRONIC OR LATENT MELIOIDOSIS , 1971, The Medical journal of Australia.
[150] P. Morris,et al. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern Territory of Australia and review of the literature. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[151] F. Castelli,et al. A case of melioidosis probably acquired by inhalation of dusts during a helicopter flight in a healthy traveler returning from Singapore. , 2015, Journal of travel medicine.
[152] N. Weisz,et al. Transient reduction of tinnitus intensity is marked by concomitant reductions of delta band power , 2008 .
[153] A. Haque,et al. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. , 2007, The Journal of infectious diseases.
[154] N. Anstey,et al. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[155] T. Inglis,et al. Burkholderia pseudomallei traced to water treatment plant in Australia. , 2000, Emerging Infectious Diseases.
[156] D. Fisher,et al. Neurological melioidosis. , 2000, Acta tropica.
[157] N. White,et al. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. , 1994, The Journal of antimicrobial chemotherapy.
[158] A. J. Clayton,et al. Melioidosis: a serological survey in military personnel. , 1973, Military medicine.
[159] W. Fletcher,et al. Melioidosis, a New Disease of the Tropics. , 1921 .